Related Experiment Video

Updated: May 10, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells

Keith I E McLuckie1, Marco Di Antonio, Heather Zecchini

  • 1Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, United Kingdom.

Journal of the American Chemical Society
|June 21, 2013
PubMed

Insights

Pyridostatin (PDS) drug enhances cancer cell death by stabilizing G-quadruplexes (G4s). This synthetic lethality approach shows promise when combined with DNA repair inhibitors or in cells with deficient DNA repair pathways.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Therapeutics

Background:

  • Synthetic lethality involves combined mutations in genes leading to cell death.
  • Pyridostatin (PDS) stabilizes G-quadruplexes (G4s), inducing DNA double-strand breaks (DSBs).
  • Ligand-induced G4 stabilization can be enhanced in cells with DNA repair deficiencies.

Purpose of the Study:

  • To investigate the synergistic effects of PDS with DNA repair inhibition.
  • To evaluate PDS efficacy in cells with impaired homologous recombination (HR) and nonhomologous end joining (NHEJ) repair pathways.

Main Methods:

  • Utilized pyridostatin (PDS) to stabilize G-quadruplexes (G4s) in cancer cells.
  • Assessed synergistic cell death with NU7441, a DNA-PK inhibitor (NHEJ pathway).
  • Examined PDS effects in BRCA2-deficient cells (impaired HR pathway).

Main Results:

  • PDS demonstrated synergistic cell death when combined with NU7441, inhibiting NHEJ.
  • BRCA2-deficient cells exhibited enhanced sensitivity to PDS, indicating synergy with impaired HR.
  • These findings highlight synthetic lethality via G4 targeting and DNA repair inhibition.

Conclusions:

  • G4 targeting ligands like PDS can act synergistically with DNA repair pathway inhibition.
  • This strategy holds potential for developing novel cancer therapeutics.
  • Targeting synthetic lethality through G4 stabilization and DNA repair defects offers a promising avenue for cancer treatment.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Single-Molecule Fluorescence Visualization of DNA Polymerase Dynamics at G-Quadruplexes05:37

Single-Molecule Fluorescence Visualization of DNA Polymerase Dynamics at G-Quadruplexes

Published on: April 4, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...